Investigating the role of RUNX2 activation across cancer evolution in lung adenocarcinoma
Investigating the role of RUNX2 activation across cancer evolution in lung adenocarcinoma
批准号:
10683738
负责人:
Lindsay Marie LaFave
金额:
$19.44万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-01 至 2024-08-31
关键词:
AddressAdvisory CommitteesBindingCancer BiologyCancer EtiologyCell LineCell secretionCellsCessation of lifeChromatinChromatin StructureCommunicationDataDependenceDevelopmentDiseaseEligibility DeterminationEngineeringEnhancersEpigenetic ProcessEventEvolutionExhibitsExtracellular MatrixGene AbnormalityGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGenetically Engineered MouseGoalsGrantHeterogeneityHistologicHistonesHomeostasisHumanImmuneImmunoprecipitationInstitutionInterventionInvestigationKRASG12DKnock-outLung AdenocarcinomaMalignant NeoplasmsMapsMediatingMentorshipModelingMutationNormal tissue morphologyOncogenesOncogenicOrganoidsPatient-Focused OutcomesPatientsPopulationPositioning AttributePostdoctoral FellowRegulator GenesReproducibilityResearchResearch EthicsResourcesRoleSamplingSecureSeriesShapesSlideSomatic MutationStromal NeoplasmSystemTP53 geneTechnologyTherapeuticTissuesTrainingTraining ActivityTranscriptional ActivationTumor stageTumor-DerivedWorkcancer cellcancer initiationcareer developmentchromatin remodelingcofactordriver mutationepigenomicsexperimental studyextracellulargenome-widegraduate schoolhuman diseasein vivomouse modelneoplastic cellnoveloverexpressionpatient subsetspost-doctoral trainingprogramsskillstargeted treatmenttranscription factortumortumor heterogeneitytumor initiationtumor microenvironmenttumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related death; however, only a subset of
patients are eligible for targeted therapies based on the presence of mutations in certain oncogenic drivers. In
addition, many therapeutic approaches target cancer-initiating events, yet tumor cells acquire alternative
dependencies during tumor progression. In this proposal, I aim to interrogate tumor progression in a genetically
engineered mouse (GEM) model of lung adenocarcinoma termed the KP (KrasG12D/+; p53f/f) model, which
faithfully recapitulates features of human disease. Transcriptional dysregulation occurs across KP tumor
progression and is not explained by the acquisition of somatic mutations, suggesting that tumor evolution is
driven predominantly by epigenetic mechanisms. In previous work leveraging single-cell chromatin profiling, I
determined that KP tumors were marked by substantial epigenetic intratumoral heterogeneity. Interestingly, I
found that late-stage populations of tumor cells exhibited progressive activation of RUNX2 transcriptional
activity. In addition, RUNX2 activated cells have increased chromatin accessibility surrounding genes involved
in extracellular secretion; however, the mechanism(s) by which RUNX2 alters chromatin state and gene
expression programs is not well-established. Based on this and other data, my central hypothesis is that
RUNX2 functions as a master regulatory transcription factor during late-stage tumor progression that
aberrantly initiates gene programs that serve to i) reshape the local tumor microenvironment, ii) facilitate
differential stromal/immune composition, and iii) contribute to increased intratumoral heterogeneity. My first
aim will interrogate the global chromatin changes and identify RUNX2-associated cofactors in RUNX2-
activated cells. The second aim will specifically focus on the role of RUNX2 activation on the remodeling of
the local tumor microenvironment. The third aim will more broadly assess the spatial localization of
heterogeneous gene expression programs in late-stage cancer cells. This proposal seeks to build on results
generated during my postdoctoral training and will serve as the initial focus of my independent research group.
My background in cancer biology and epigenetics from my graduate school training, paired with my extensive
expertise in GEM models and epigenomic technologies from my postdoctoral training, positions me for a
successful transition to independence. As part of this grant, I will assemble an advisory team at my institution
to support my transition and career development training activities outlined in this proposal. I will take
advantage of the varied resources at my postdoctoral institutions and the institution where I secure an
independent position to develop skills related to mentorship, communication, and research ethics. Overall, the
outlined training plain in this proposal will greatly support my continued development, with the goal of making
substantial contributions in the fields of epigenetics and cancer biology.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Investigating the role of RUNX2 activation across cancer evolution in lung adenocarcinoma
-
批准号:10191577
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2021
-
负责人:Lindsay Marie LaFave
-
依托单位:
Investigating the role of RUNX2 activation across cancer evolution in lung adenocarcinoma
-
批准号:10470749
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2021
-
负责人:Lindsay Marie LaFave
-
依托单位:
Investigation of the Role of BAP1 in Normal and Malignant Hematopoiesis
-
批准号:8595542
-
项目类别:
-
资助金额:$4.22万
-
财政年份:2013
-
负责人:Lindsay Marie LaFave
-
依托单位:
Investigation of the Role of BAP1 in Normal and Malignant Hematopoiesis
-
批准号:8696632
-
项目类别:
-
资助金额:$4.27万
-
财政年份:2013
-
负责人:Lindsay Marie LaFave
-
依托单位:
海外基金